Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 1Dermatologic 1

Conditions

Ovarian Neoplasms 2Neoplasms 2Melanoma 2Carcinoma, Non-Small-Cell Lung 2Brain Neoplasms 2Oligodendroglioma 1Neoplasm Metastasis 1Lung Neoplasms 1Gliosarcoma 1Glioblastoma 1Central Nervous System Neoplasms 1Carcinoma 1Astrocytoma 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1

Interventions

pembrolizumab 180Gemcitabine 168Paclitaxel 150Carboplatin 134Bevacizumab 126Cisplatin 113Docetaxel 112Cyclophosphamide 109Exercise 97Nivolumab 93Fluorouracil 88Capecitabine 85Dexamethasone 81Irinotecan 74Radiotherapy 68Oxaliplatin 68Pemetrexed 66Standard of Care 64Leucovorin 63Cetuximab 59Sorafenib 53Erlotinib Hydrochloride 53Drug Therapy 53Blood Specimen Collection 51Doxorubicin 50atezolizumab 48trametinib 47Ipilimumab 47Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Neoplasms × cositecan × Clear all
NCT00062491 2020-03-12

Study of Karenitecin (BNP1350) to Treat Malignant Melanoma

BioNumerik Pharmaceuticals, Inc.

Phase 2 Completed
46 enrolled
Dermatologic

Melanoma, Neoplasms

NCT00477282 2020-03-12

Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer

BioNumerik Pharmaceuticals, Inc.

Phase 3 Completed
509 enrolled
Gynecologic

Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡